Schubert & Co’s 10x Genomics TXG Stock Holding History

Schubert & Co’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	–	–	1599
2022 Q1	$0	Hold	2	–	–	﹤0.01%	1343
2021 Q4	$0	Buy	+2	New	+$306	﹤0.01%	1294

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Schubert & Co's TXG Position: Q2 2022 in Review

Schubert & Co sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 2 shares.

Schubert & Co first reported a position in TXG in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

Schubert & Co reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
Schubert & Co sold 2 10x Genomics shares in Q2 2022.
Schubert & Co first reported a position in 10x Genomics in Q4 2021 and held it in 2 quarters.
Schubert & Co's 10x Genomics position peaked at $0 in Q1 2022.
254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Schubert & Co's 13F filing for Q2 2022, filed 1 Aug 2022.